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BOOK REVIEWS
Catalog of Chromosome Abberations in Cancer, 2nd
ed., Progress and Topics in Cytogenetics, Vol. 5. By
F. Mitelman. A.R. Liss (1985). £75.00. xvi+606 pp.
ISBN 0 8451 2405 6.
This is a remarkable compilation of all the
chromosome abnormalities observed in leukaemias
and solid tumours which appear to be clonal in
origin. A clone is defined as 'at least two cells with
the same extra chromosome or structural aberration
or three cells with the same missing chromosome'.
The aberrations are listed by the number of the
chromosome involved and within each chromosome
by disease classification. The second edition is an
improvement on the first, not only because of a
substantial increase in the number of cases, but also
because the lay out of the disease classification is
greatly improved. This is a very useful data base
but that is all that it is. The reader must do a lot of
work to get information on specific associations.
Though there is no attempt at analysis or
interpretation, this is not a criticism of this work at
this stage in its development. Now that the
foundations have been laid Dr Mitelman can push
the project forward, not only by increasing the size
of the data base but by beginning to do the kinds
of analysis that would prove more interesting to the
general reader. It would be of value, for example,
to list specific aberrations which have been seen in
more than a certain number of cases, perhaps
setting different levels to give an indication of
different degrees of specificity. It would also be
useful to see a breakpoint analysis since there is
available here a very much larger number of cases
than have been used in previous analyses of this
type.
It must be emphasized that this is a reference
work aimed at people working specifically in the
field of chromosome aberrations in cancer cells. But
for them the book will be of great value. For
example it took only a few minutes to establish that
of 108 cases of chronic lymphocytic leukaemia, 40
had an abnormality of chromosome 14, that the
two commonest abnormalities are a translocation t
(11;14) (ql3;q32), and an inversion, inv 14
(ql1; q32) which occur in 9 and 7 cases respectively,
and that the breakpoint occurred on 22 occasions
at or near 14q32.
The main value, however, will almost certainly
come in attempts to link up specific genes or
DNA polymorphisms with chromosome rearrange-
ments which occur repeatedly in the same cancer or
in many different cancers. It would be useful if,
eventually, the data base could be made available
on line, since there is enough work here to keep
many investigators busy for a long time.
This is an expensive book. No one would want
to buy it to read, but no one who is involved in
cancer cytogenetics can afford to be without it.
D.G. Harnden
Neoplastic Diseases of the Blood. Edited by P.H.
WIERNIK, G.P. CANELLOS, R.A. KYLE & C.A.
SCHIFFER. Pp. 1190, plus 4 colour plates, Churchill
Livingstone, Edinburgh. £175 (2 volumes).
The editors say that this 2-volume work is intended
to be an 'encyclopedia of haematological malig-
nancies' and it is certainly the largest book so far
published in this particular field. They have
recruited the help of 70 authors who, between
them, have written 57 chapters. The book is divided
into 5 major sections dealing respectively with
chronic myelo- and lymphoproliferative disorders,
acute leukaemias, myeloma and other immuno-
proliferative diseases, lymphomas, and supportive
care of patients with neoplastic disorders. Bone
marrow transplantation is included in this last
section. Each chapter is followed by a brief
summary, and the bibliography is usually
comprehensive. The best section is, perhaps, that
dealing with myeloma and related diseases, edited
by Dr Robert Kyle. The chapters on the diagnosis
and management of myeloma, (Dr R. Alexanian)
and on unusual manifestations of plasma cell
neoplasia, (Dr D.E. Bergsagel and Dr W.
Pruzanski), provide the clinician with information,
often based on personal data, not always readily
available elsewhere. Amongst the excellent
contributions to this section are historical notes
about the various types of immunoproliferative
disease. Most physicians are aware that the peculiar
biochemical features of multiple myeloma were first
described by Dr Henry Bence-Jones and Dr
Thomas Watson in 1845; few will be aware that
amyloidosis was described 200 years earlier!
Elsewhere, the section on the morphology of acute
leukaemia by Dr John Bennett includes interesting
data on the reproducibility of the FAB
classifications. It is significant that, even in the
hands of experts, there are difficulties in separating
M2 from M4, and M4 from M5. The problem of
delineating acute erythroleukaemia (M6) is still not
entirely resolved, especially when the myeloblastic
component is very small. There may be difficulty in
distinguishing such cases morphologically from
myelodysplasia, though the clinical behaviour of the
two diseases is usually different. Chronic